Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Genzyme Tissue Repair (GZTR) -- Ignore unavailable to you. Want to Upgrade?

To: Knighty Tin who wrote (2518)	3/6/2000 10:12:00 AM
From: Greg Jung	Read Replies (1) \| Respond to of 2553

Merger Alert: GZTR is involved in the 3-way to be held with Biomatrix (BXM). Genzyme Biosurgery. BXM holders get guaranteed $37/share cash or 1 share in new company, GZTR get .335 share GZSP gets .606 share. Based on $37 value GZTR and GZSP closed at 26% discounts. GZTR opened up+1, dropped to hit my bid at 9 1/2 :) about 10 am and seems to have bounced back up. BXM makes actual earnings and has increasing revenues from new products.

To: Knighty Tin who wrote (2518)	12/12/2000 6:48:28 AM
From: Micawber	Read Replies (1) \| Respond to of 2553

December 12, 2000 Market Place: Tracking Stocks' Luster Masks Risk and Conflicts of Interest By GRETCHEN MORGENSON ...Genzyme shareholders are mulling over the creation of a new tracking stock that would result from an acquisition proposed by management. Two of the Genzyme Corporation's units covered by tracking stocks would buy the company, Biomatrix, using money borrowed by the parent Genzyme. While the purchase could increase the market prices of the tracking stocks, which are to be combined, the liability for the loan would ultimately fall on the parent company, leaving it to shoulder most of the risk yet receive little of the benefit... nytimes.com